APC301
Multidrug-resistant bacterial infections (MBL & SBL-producing Enterobacterales)
Phase 1Active
Key Facts
Indication
Multidrug-resistant bacterial infections (MBL & SBL-producing Enterobacterales)
Phase
Phase 1
Status
Active
Company
About AdjuTec Pharma
AdjuTec Pharma is a private, preclinical-stage biotech founded in 2019, originating from research at the University of Oslo. The company is developing adjuvant therapies, specifically β-lactamase inhibitors, designed to break bacterial resistance and rescue last-line antibiotics like carbapenems and cephalosporins. Its lead candidate, APC148, has completed a First-In-Man study, positioning the company to tackle a critical and growing global health crisis. Backed by private funding, public grants, and a founding professor-emeritus as its largest shareholder, AdjuTec aims to bring its novel resistance-breaking combinations to market.
View full company profile